News

Image source: The Motley Fool.

AstraZeneca Plc (NASDAQ: AZN)Q4 2024 Earnings CallFeb 06, 2025, 6:00 a.m. ET

Operator

Continue reading

Source Fool.com

Realty Income (NYSE: O) and AT&T (NYSE: T) are both popular stocks for income-oriented dividend investors. Realty is one of the world's largest real estate investment trusts (REITs), and AT&T is one

From the end of 2023 through Jan. 28, shares of AT&T (NYSE: T) rose 48%. Although it had been offering an ultra-high dividend yield, the company hasn't altered its payout since reducing it in 2022.

AT&T (NYSE: T) reported excellent quarterly results that increased the stock price.

*Stock prices used were the afternoon prices of Jan. 28, 2025. The video was published on Jan. 30, 2025.

Continue

It can be exciting to buy a stock that has been red hot and to jump on the bandwagon -- but doing so can come with significant risks. At some point, there's a danger that the stock's rally could

Shares of telecom giant AT&T (NYSE: T) were surging on Monday for good reason. The company reported estimate-busting results, reiterated its 2025 outlook, and updated investors on its debt reduction

Telecom giant AT&T (NYSE: T) beat expectations on all fronts when it reported its fourth-quarter results on Monday. There was a lot for investors to like. The company hit or exceeded all its

Dividend sustainability concerns have weighed on AT&T (NYSE: T) in recent years. The telecom giant had previously cut its payout by nearly 50% in 2022 to retain additional cash to invest in its

AT&T (NYSE: T) stock is seeing big gains in Monday's trading despite a bearish backdrop for the broader market. The company's share price was up 7% as of 3:15 p.m. ET. Meanwhile, the S&P 500

Image source: The Motley Fool.

AT&T (NYSE: T)Q4 2024 Earnings CallJan 27, 2025, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Telecommunications giant AT&T (NYSE:T) reported fourth-quarter and full-year 2024 earnings on Monday, Jan. 27, that topped analyst consensus estimates. Adjusted earnings per share (EPS) of $0.54

Finding genuinely cheap stocks in a pricey stock market can be tough. Some stocks may look cheap based on standard valuation metrics, but they're anything but once you factor in their growth

AT&T (NYSE: T) is a leading telecom provider in the U.S. While investors often load up on the stock for its dividend, it has also generated some decent returns over the past year. During that

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating for

Telecom giant AT&T (NYSE: T) has been steadily gaining wireless and fiber internet subscribers over the past few years. Over the two-year period that ended on Sept. 30, AT&T grew its total wireless

Shares of biotech Summit Therapeutics (NASDAQ: SMMT) skyrocketed 583.7% in 2024, according to data from S&P Global Market Intelligence.

Summit was an early-stage biotechnology stock heading into the

Dividend stocks trading at discounted prices can make for great investments if you're willing to be patient. That's because, assuming their payouts are sustainable, you can lock in a higher yield

As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term. For long-term investors, now may be a good time to reevaluate the

The best dividend stocks can provide you with bountiful streams of passive income. With their lower risk and volatility profiles, these stalwart stocks should also help you protect your wealth while

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn't

U.K.-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country

Summit Therapeutics (NASDAQ: SMMT) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. The company's shares are up by

Shares of telecom giant AT&T (NYSE: T) have soared about 35% so far this year, delivering market-beating returns to investors after years of trouble. The company's failed efforts to become a media